The global nanomedicine market is anticipated to reach USD
350.8 billion by 2025, according to a new report by Grand View Research, Inc.
Development of novel nanotechnology-based drugs and therapies is driven by the
need to develop therapies that have fewer side effects and that are more
cost-effective than traditional therapies, in particular for cancer.
Application of nanotechnology-based contrast
reagents for diagnosis and monitoring of the effects of drugs on an
unprecedented short timescale is also attributive drive growth in the coming
years. Additionally, demand for biodegradable implants with longer lifetimes
that enable tissue restoration is anticipated to influence demand.
As per the WHO factsheet, cancer is found to
be one of the major causes of mortality and morbidity worldwide, with
approximately 14 million new cases in 2012 and 8.2 million cancer-related
deaths. Thus, demand for nanomedicine in order to curb such high incidence rate
is expected to boost market progress during the forecast period.
Solutions such as nanoformulations with
triggered release for tailor-made pharmacokinetics, nanoparticles for local
control of tumor in combination with radiotherapy, and functionalized
nanoparticles for targeted in-vivo activation of stem cell production are
anticipated to drive R&D, consequently resulting in revenue generation in
the coming years.
Biopharmaceutical and medical devices
companies are actively engaged in development of novel products as demonstrated
by the increasingly growing partnerships between leading enterprises and
nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk
signed a global collaboration and a licensing agreement for development and
discovery of innovative drugs with multi-specific nanobodies. This strategic
partnership is anticipated to rise the net annual sales of the products
uplifting the market growth.
However, in contrary with the applications of
nanotechnology, the entire process of lab to market approval is a tedious and
expensive one with stringent regulatory evaluation involved thereby leading
investors to remain hesitant for investments.
Browse full research report on Nanomedicine
Market:
https://www.grandviewresearch.com/industry-analysis/nanomedicine-market
Further key
findings from the report suggest:
- Therapeutics accounted for the largest share
of market revenue in 2016 owing to presence of nanoemulsions,
nanoformulations, or nanodevices
- These devices possess the ability to cross
biological barriers. Moreover, presence of drugs such as Doxil, Abraxane,
and Emend is attributive for higher revenue generation
- Presence of substantial number of products
manufactured through the use of microbial sources can be attributed for
the largest share
- In-vitro diagnostics is
expected to witness lucrative progress as a result of R&D carried out
in this segment
- Introduction of nano-enabled biomarkers,
vectors and contrast agents with high-specificity and sensitivity are
attributive for projected progress
- Clinical cardiology is expected to witness the
fastest growth through to 2025 owing to development in
nano-functionalization and modification of surfaces for increased
biocompatibility of implants in treatment of late thrombosis
- Moreover, an abundance of research
publications and patent filings from European region with a share of about
25% in nanomedicine-related publications is supportive for revenue
generation from European economies
- Asia Pacific is estimated to witness the
fastest growth over the forecast period
- Factors responsible include government and
regulatory authorities that have implemented a framework to encourage
R&D collaborations and framework extension.
- Key players operating in this industry include
Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis
Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
- Active expansion strategies are undertaken by
a number of the major market entities in order to strengthen their
position
- North America dominated the industry in 2016,
accounting for a 42% of total revenue
- Presence of key participants operating in the
region are involved in collaborative activities are attributive for the
largest share of North America in sector revenue
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/nanomedicine-market/request/rs1
Grand
View Research has segmented the nanomedicine market on the basis of product,
application, nanomolecule type, and region:
Nanomedicine
Product Outlook (Revenue, USD Billion; 2013 - 2025)
- Therapeutics
- Regenerative
medicine
- In-vitro diagnostics
- In-vivo diagnostics
- Vaccines
Nanomedicine
Application Outlook (Revenue, USD Billion; 2013 - 2025)
- Clinical Oncology
- Infectious diseases
- Clinical Cardiology
- Orthopedics
- Others
Nanomedicine
Nanomolecule Type Outlook (Revenue, USD Billion; 2013 - 2025)
- Nanoparticles
- Metal & Metal
Oxide Nanoparticles
- By Type
- Gold
Nanoparticles
- Silver
Nanoparticles
- Iron Oxide
Nanoparticles
- Alumina
Nanoparticles
- Gadolinium Oxide
Nanoparticles
- Others
- By Application
- In-vivo Imaging
- Targeted Drug
Delivery
- Proton Therapy
- In-vitro assays
- Cell &
Phantom Imaging
- Liposomes
- Polymers &
polymer drug conjugates
- Hydrogel
nanoparticles
- Dendrimers
- Inorganic
nanoparticles
- Nanoshells
- Nanotubes
- Nanodevices
Nanomedicine
Regional Outlook (Revenue, USD Billion; 2013 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East and
Africa (MEA)
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment